CA-170

N/A

Report date: 2025/05/28 16:57:10
NME

Base Information

Drug NameCA-170
Drug Alias NameCA-170AUPM-170
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-domain Ig suppressor of T-cell activation inhibitorsProgrammed death-ligand 1 blockersProgrammed death-ligand 2 inhibitors
TargetsV-domain Ig suppressor of T-cell activationProgrammed death-ligand 1Programmed death-ligand 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAurigene
China Registration ClassN/A

Develop Information

Active CompaniesAurigene Discovery Technologies Ltd
Inactive CompaniesCuris Inc
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A